TNF-α antagonists like Infliximab hinder osteoclastogenesis via decreasing, theoretically or actually, RANKL, TNF-α, and M-CSF production (Kitaura et al., 2005; Kim et al., 2017a), while skin irritation like psoriasis and eczema are observed. Here, TNFSF11 is linked to Eczematoid dermatitis.